, Volume 64, Issue 1, pp 196–199 | Cite as

Acromegaly can be cured by first-line pasireotide treatment?

  • Sabrina Chiloiro
  • Antonella Giampietro
  • Antonio Bianchi
  • Tommaso Tartaglione
  • Chiara Bima
  • Maria Gabriella Vita
  • Maurizio Spinello
  • Alfredo Pontecorvi
  • Laura De MarinisEmail author
Research Letter

Pasireotide long-acting release (LAR) is a new generation long-acting somatostatin multi-receptor ligand, with an increased affinity for the five subtypes of the somatostatin receptor compared with first-generation somatostatin analogues (SSAs) [1]. Several studies have proven the efficacy of pasireotide LAR in reaching the biochemical control of acromegaly, both in medically naive and in patients resistant to conventional SSA [2, 3, 4, 5, 6, 7]. We report here the case of a patient with acromegaly who was successfully treated with first-line pasireotide LAR.

Case report

The patient’s medical history concerning the present case started on April 2009, at the age of 68 years, when the patient underwent urologic specialist evaluation for a recent occurrence of nocturia, pollakiuria, and dysuria. The specific prostate antigen (PSA) value was normal. However, the ultrasound evaluation of the prostatic gland showed an increased volume of the gland with a transversal diameter of 57 mm. The...


Compliance with ethical standards

Conflict of interest

Medical writing and editorial assistance were provided by Luca Giacomelli, PhD, and Aashni Shah, on behalf of Content Ed Net; this assistance was funded by Novartis Farma (Origgio, Italy). MS is Novartis Farma employee. The remaining authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from the individual participant included in the study.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    M.R. Gadelha, M.D. Bronstein, T. Brue et al. Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, Phase 3 trial. Lancet Diabetes Endocrinol. 2(11), 875–884 (2014). CrossRefGoogle Scholar
  2. 2.
    M. Sheppard, M.D. Bronstein, P. Freda et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18(3), 385–894 (2015). CrossRefGoogle Scholar
  3. 3.
    A. Colao, M.D. Bronstein, P. Freda et al. Pasireotide versus octreotidein acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014)CrossRefGoogle Scholar
  4. 4.
    S. Tahara, M. Murakami, T. Kaneko, A. Shimatsu, Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr. J. 64(7), 735–747 (2017). CrossRefGoogle Scholar
  5. 5.
    I. Shimon, W. Saeger, L.E. Wildemberg, M.R. Gadelha, Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. Horm. (Athens). 16(1), 84–91 (2017)Google Scholar
  6. 6.
    M. Fleseriu, E. Rusch, E.B. Geer, ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55(1), 247–255 (2017). CrossRefGoogle Scholar
  7. 7.
    M.D. Bronstein, M. Fleseriu, S. Neggers et al. Pasireotide C2305 Study Group. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr. Disord. 16, 16 (2016). CrossRefGoogle Scholar
  8. 8.
    J.S. Chang, H.M. Tseng, T.C. Chang, Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly. J. Formos. Med. Assoc. 115(6), 475–480 (2016). CrossRefGoogle Scholar
  9. 9.
    A.G. Osborn, K.L. Salzman, M.D. Jhaveri, A.J. Barkovich, Sella and pituitary. in Diagnostic Imaging Brain. (Alirsys Elsevier, Philadelphia, 2016), 3, ch 292, pp. 1056–1059Google Scholar
  10. 10.
    C. Capatina, W. Inder, N. Karavitaki, J.A. Wass, Management of endocrine disease: pituitary tumour apoplexy. Eur. J. Endocrinol. 172(5), R179–R190 (2015)CrossRefGoogle Scholar
  11. 11.
    A. Giustina, P. Chanson, D. Kleinberg et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10, 243–248 (2014)CrossRefGoogle Scholar
  12. 12.
    D. Iacovazzo, E. Carlsen, F. Lugli, S. Chiloiro, S. Piacentini, A. Bianchi, A. Giampietro, M. Mormando, A.J. Clear, F. Doglietto, C. Anile, G. Maira, L. Lauriola, G. Rindi, F. Roncaroli, A. Pontecorvi, M. Korbonits, L. De Marinis, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 174(2), 241–250 (2016). CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Sabrina Chiloiro
    • 1
  • Antonella Giampietro
    • 1
  • Antonio Bianchi
    • 1
  • Tommaso Tartaglione
    • 2
  • Chiara Bima
    • 1
  • Maria Gabriella Vita
    • 3
  • Maurizio Spinello
    • 4
  • Alfredo Pontecorvi
    • 1
  • Laura De Marinis
    • 1
    Email author
  1. 1.Pituitary Unit, Fondazione Policlinico Universitario Agostino GemelliUniversità Cattolica del Sacro CuoreRomeItaly
  2. 2.Department of Radiology, Istituto Dermopatico dell’ImmacolataRome and Università Cattolica del Sacro CuoreRomeItaly
  3. 3.Neurology Unit, Fondazione Policlinico Universitario Agostino GemelliUniversità Cattolica del Sacro CuoreRomeItaly
  4. 4.Novartis Farma SpAOriggioItaly

Personalised recommendations